- Home
- KMI vs TNGX Comparison
KMI vs TNGX Comparison
Compare KMI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMI
- TNGX
- Stock Information
- Founded
- KMI 1936
- TNGX 2014
- Country
- KMI United States
- TNGX United States
- Employees
- KMI N/A
- TNGX N/A
- Industry
- KMI Natural Gas Distribution
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- KMI Utilities
- TNGX Health Care
- Exchange
- KMI Nasdaq
- TNGX Nasdaq
- Market Cap
- KMI 59.2B
- TNGX 723.2M
- IPO Year
- KMI 2011
- TNGX N/A
- Fundamental
- Price
- KMI $27.68
- TNGX $7.87
- Analyst Decision
- KMI Buy
- TNGX Strong Buy
- Analyst Count
- KMI 14
- TNGX 6
- Target Price
- KMI $29.86
- TNGX $10.00
- AVG Volume (30 Days)
- KMI 11.5M
- TNGX 1.7M
- Earning Date
- KMI 10-15-2025
- TNGX 11-05-2025
- Dividend Yield
- KMI 4.23%
- TNGX N/A
- EPS Growth
- KMI 11.35
- TNGX N/A
- EPS
- KMI 1.22
- TNGX N/A
- Revenue
- KMI $15,969,000,000.00
- TNGX $24,296,000.00
- Revenue This Year
- KMI $11.25
- TNGX $20.42
- Revenue Next Year
- KMI $5.46
- TNGX N/A
- P/E Ratio
- KMI $22.71
- TNGX N/A
- Revenue Growth
- KMI 3.97
- TNGX N/A
- 52 Week Low
- KMI $21.46
- TNGX $1.03
- 52 Week High
- KMI $31.48
- TNGX $8.98
- Technical
- Relative Strength Index (RSI)
- KMI 60.39
- TNGX 66.70
- Support Level
- KMI $27.07
- TNGX $6.38
- Resistance Level
- KMI $27.81
- TNGX $6.90
- Average True Range (ATR)
- KMI 0.45
- TNGX 0.46
- MACD
- KMI 0.12
- TNGX 0.09
- Stochastic Oscillator
- KMI 87.66
- TNGX 90.50
About KMI Kinder Morgan Inc.
Kinder Morgan is one of the largest midstream energy firms in the US, with an interest in or an operator on more than 80,000 miles of gas, refined products, and carbon dioxide pipelines. The company also owns one of the largest portfolios of gas and refined products storage and terminals. Most of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.